Royalty Pharma PLC - CL
RPRX59.9702.11% ( +1.240 )
Royalty Pharma PLC - CL (RPRX)
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its por...
- Open
- 58.913
- High
- 60.080
- Low
- 58.913
- Prev. Close
- 58.730
- Volume
- 3.14M
- Turnover
- 187.47M
- Avg Price
- 59.723
- Bid/Ask Ratio
- --
- Amplitude
- 1.99%
- 52wk High
- 60.080
- Volume Ratio
- 0.89
- Turnover Ratio
- 0.85%
Royalty Pharma PLC - CL Analyst Rating
View MoreForecast & Rating
Jul 22, 2026Price forecast
$59.89-0.14%
Forecast & RatingBuy
9analysts
- Strong buy55.56%
- Buy22.22%
- Hold22.22%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · 2 days ago, 03:01 AM
Dai ichi Life Insurance Company Ltd Has $6.19 Million Stock Position in Royalty Pharma PLC $RPRX
- Tip Ranks · Jul 24 at 07:25 AM
Analyst Reiterates Buy on Prothena, Maintains $30 Price Target on Differentiated TTR-Depleter Opportunity
- Market Beat · Jul 24 at 03:01 AM
CI Investments Inc. Has $8.33 Million Stock Holdings in Royalty Pharma PLC $RPRX
- StockTitan · Jul 21 at 10:05 PM
Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune | RPRX Stock News
- StockTitan · Jul 17 at 07:15 AM
Royalty Pharma declares third quarter 2026 dividend | RPRX Stock News
- PUBT · Jul 15 at 03:19 PM
Royalty Pharma to report Q2 2026 results, host conference call
